MAGEA1 and melanoma: The ex vivo manipulation of DCs using melanoma-derived antigenic TCLs effectively induced signals for melanoma-associated antigen-1 (MAGE-1)-specific CTL responses, and two out of sixteen patients showed long-lasting immune responses over 6 months by successfully modulating antitumor immunity [85].